UniProt P02766
Transthyretin (P02766)
Transthyretin (UniProt P02766): 627 experimental structures and 1 predicted model on GenesisL1, 66 ligands bound, 40 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- P02766
- Protein
- Transthyretin
- Experimental structures
- 627
- Predicted models
- 1
- Ligands
- 66
- Pockets
- 40 · 4 records with a druggable one
Structures
628 records of P02766 in the MolNFT archive: 627 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1BM7 | Human transthyretin (prealbumin) complex with flufenamic acid (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]… | x-ray diffraction | A, B | — | — |
| 1BM7 | Human transthyretin (prealbumin) complex with flufenamic acid (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]… | x-ray diffraction | A, B | — | — |
| 1BMZ | Human transthyretin (prealbumin) | x-ray diffraction | A, B | — | — |
| 1BMZ | Human transthyretin (prealbumin) | x-ray diffraction | A, B | — | — |
| 1BZ8 | Transthyretin (del VAL122) | x-ray diffraction | A, B | — | — |
| 1BZ8 | Transthyretin (del VAL122) | x-ray diffraction | A, B | — | — |
| 1BZD | Tertiary structures of three amyloidogenic transthyretin variants and implications for amyloid… | x-ray diffraction | A, B | — | — |
| 1BZD | Tertiary structures of three amyloidogenic transthyretin variants and implications for amyloid… | x-ray diffraction | A, B | — | — |
| 1BZE | Tertiary structures of three amyloidogenic transthyretin variants and implications for amyloid… | x-ray diffraction | A, B | — | — |
| 1BZE | Tertiary structures of three amyloidogenic transthyretin variants and implications for amyloid… | x-ray diffraction | A, B | — | — |
| 1DVQ | Crystal structure of human transthyretin | x-ray diffraction | A, B | — | — |
| 1DVQ | Crystal structure of human transthyretin | x-ray diffraction | A, B | — | — |
| 1DVS | Crystal structure of human transthyretin in complex with resveratrol | x-ray diffraction | A, B | — | — |
| 1DVS | Crystal structure of human transthyretin in complex with resveratrol | x-ray diffraction | A, B | — | — |
| 1DVT | Crystal structure of human transthyretin in complex with flurbiprofen | x-ray diffraction | A, B | — | — |
| 1DVT | Crystal structure of human transthyretin in complex with flurbiprofen | x-ray diffraction | A, B | — | — |
| 1DVU | Crystal structure of human transthyretin in complex with dibenzofuran-4,6-dicarboxylic acid | x-ray diffraction | A, B | — | — |
| 1DVU | Crystal structure of human transthyretin in complex with dibenzofuran- 4,6-dicarboxylic acid | x-ray diffraction | A, B | — | — |
| 1DVX | Crystal structure of human transthyretin in complex with diclofenac | x-ray diffraction | A, B | — | — |
| 1DVX | Crystal structure of human transthyretin in complex with diclofenac | x-ray diffraction | A, B | — | — |
| 1DVY | Crystal structure of transthyretin in complex with N-(M-trifluoromethylphenyl)… | x-ray diffraction | A, B | — | — |
| 1DVY | Crystal structure of transthyretin in complex with N-(M- trifluoromethylphenyl)… | x-ray diffraction | A, B | — | — |
| 1DVZ | Crystal structure of human transthyretin in complex with O-trifluoromethylphenyl anthranilic acid | x-ray diffraction | A, B | — | — |
| 1DVZ | Crystal structure of human transthyretin in complex with O- trifluoromethylphenyl anthranilic acid | x-ray diffraction | A, B | — | — |
| 1E3F | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1E3F | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1E4H | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1E4H | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1E5A | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1E5A | Structure of human transthyretin complexed with bromophenols: a new mode of binding | x-ray diffraction | A, B | — | — |
| 1ETA | The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic val… | x-ray diffraction | 1, 2 | — | — |
| 1ETA | The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic val… | x-ray diffraction | 1, 2 | — | — |
| 1ETB | The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic val… | x-ray diffraction | 1, 2 | — | — |
| 1ETB | The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic val… | x-ray diffraction | 1, 2 | — | — |
| 1F41 | Crystal structure of human transthyretin at 1.5A resolution | x-ray diffraction | A, B | — | — |
| 1F41 | Crystal structure of human transthyretin at 1.5A resolution | x-ray diffraction | A, B | — | — |
| 1F86 | Transthyretin THR119MET protein stabilisation | x-ray diffraction | A, B | — | — |
| 1F86 | Transthyretin THR119MET protein stabilisation | x-ray diffraction | A, B | — | — |
| 1FH2 | Transthyretin stability as a key factor in amyloidogenesis | x-ray diffraction | A, B | — | — |
| 1FH2 | Transthyretin stability as a key factor in amyloidogenesis | x-ray diffraction | A, B | — | — |
| 1FHN | Transthyretin stability as a key factor in amyloidogenesis | x-ray diffraction | A, B | — | — |
| 1FHN | Transthyretin stability as a key factor in amyloidogenesis | x-ray diffraction | A, B | — | — |
| 1G1O | Crystal structure of the highly amyloidogenic transthyretin mutant ttr G53S/E54D/L55S | x-ray diffraction | A, B, C, D | — | — |
| 1G1O | Crystal structure of the highly amyloidogenic transthyretin mutant ttr G53S/E54D/L55S | x-ray diffraction | A, B, C, D | — | — |
| 1GKO | An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denatured | x-ray diffraction | A, B, C, D | — | — |
| 1GKO | An engineered transthyretin monomer that is non-amyloidogenic - unless partially denatured | x-ray diffraction | A, B, C, D | — | — |
| 1ICT | Monoclinic form of human transthyretin complexed with thyroxine (T4) | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 1ICT | Monoclinic form of human transthyretin complexed with thyroxine (T4) | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 1III | Crystal structure of the transthyretin mutant ttr Y114C-data collected at room temperature | x-ray diffraction | A, B | — | — |
| 1III | Crystal structure of the transthyretin mutant ttr Y114C-data collected at room temperature | x-ray diffraction | A, B | — | — |
| 1IIK | Crystal structure of the transthyretin mutant ttr Y114C-data collected at cryo temperature | x-ray diffraction | A, B | — | — |
| 1IIK | Crystal structure of the transthyretin mutant ttr Y114C-data collected at cryo temperature | x-ray diffraction | A, B | — | — |
| 1IJN | Crystal structure of the transthyretin mutant TTR C10A/Y114C | x-ray diffraction | A, B | — | — |
| 1IJN | Crystal structure of the transthyretin mutant ttr C10A/Y114C | x-ray diffraction | A, B | — | — |
| 1QAB | The structure of human retinol binding protein with its carrier protein transthyretin reveals… | x-ray diffraction | A, B, C, D | — | — |
| 1QAB | The structure of human retinol binding protein with its carrier protein transthyretin reveals… | x-ray diffraction | A, B, C, D | — | — |
| 1QWH | a covalent dimer of transthyretin that affects the amyloid pathway | x-ray diffraction | A, B | — | — |
| 1QWH | A covalent dimer of transthyretin that affects the amyloid pathway | x-ray diffraction | A, B | — | — |
| 1RLB | Retinol binding protein complexed with transthyretin | x-ray diffraction | A, B, C, D | — | — |
| 1RLB | Retinol binding protein complexed with transthyretin | x-ray diffraction | A, B, C, D | — | — |
568 records more on the page itself.
Ligands
- NA · Sodium ion · in 16 records
- CA · Calcium ion · in 11 records
- 3MI · 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid · in 7 records
- 1FL · 5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid · in 4 records
- RE · Rhenium · in 4 records
- HH9 · 4-chloranyl-9-oxidanylidene-xanthene-2-carboxylic acid · in 3 records
- TCW · Tolcapone · in 3 records
- 6J1 · 2,6-Dinitro-p-cresol · in 2 records
- 6J3 · 2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid · in 2 records
- 7VG · {3-chloro-4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl}boronic acid · in 2 records
- 9TF · Purpurin · in 2 records
- F4Z · 3,5,6-trichloro-2-pyridinol · in 2 records
- FE · Fe (III) ion · in 2 records
- FFE · [bis(oxidanyl)-[tetrakis(oxidanyl)ferriooxy]ferrio]oxy-pentakis(oxidanyl)iron · in 2 records
- FQ7 · 2-[(3,5-dichlorophenyl)amino]benzoic acid · in 2 records
- J5R · 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid · in 2 records
- J6O · 2-[3,4-bis(oxidanyl)phenyl]-3-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one · in 2 records
- LVE · 3-O-methyltolcapone · in 2 records
- MN · Manganese (II) ion · in 2 records
- SBK · Triclopyr · in 2 records
- SO4 · Sulfate ion · in 2 records
- 1N1 · N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide · in 1 record
- 6B5 · 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-chromen-4-one · in 1 record
- 6JD · 4-(4-hydroxyphenyl)sulfonylphenol · in 1 record
- 7LU · 2-[3,4-bis(oxidanyl)phenyl]-7-chloranyl-5-oxidanyl-chromen-4-one · in 1 record
- 7UV · (3-{(E)-2-[2-chloro-4-(hydroxyboranyl) phenyl]ethenyl}phenyl)boronic acid · in 1 record
- 8KZ · 3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxy-phenol · in 1 record
- 8PF · pentadecafluorooctanoic acid · in 1 record
- 9PS · 4-[(~{E})-2-naphthalen-2-ylethenyl]benzene-1,2-diol · in 1 record
- AJU · 2,3,5,6,8,9,11,12,14,15-decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecine-18-carboxylic acid · in 1 record
Experiment against prediction
- 1QWH chain A against the predicted model P02766: TM-score 0.99, RMSD 0.32 Å
- 1BM7 chain A against the predicted model P02766: TM-score 0.99, RMSD 0.35 Å
- 1BMZ chain A against the predicted model P02766: TM-score 0.99, RMSD 0.36 Å
- 1TZ8 chain A against the predicted model P02766: TM-score 0.99, RMSD 0.40 Å
- 2B16 chain A against the predicted model P02766: TM-score 0.99, RMSD 0.42 Å
- 1DVX chain A against the predicted model P02766: TM-score 0.99, RMSD 0.41 Å
- 1DVY chain A against the predicted model P02766: TM-score 0.99, RMSD 0.41 Å
- 1FH2 chain A against the predicted model P02766: TM-score 0.99, RMSD 0.40 Å
- 1X7S chain A against the predicted model P02766: TM-score 0.99, RMSD 0.42 Å
- 2B9A chain A against the predicted model P02766: TM-score 0.99, RMSD 0.39 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.